Introduction {#s1}
============

*Streptococcus pneumoniae* (pneumococcus) and respiratory syncytial virus (RSV) are the leading causes of lower respiratory tract infections (LRTIs) amongst children and older adults ([@B1], [@B2]). Importantly, co-infections with these pathogens are becoming increasingly recognized as a major contributor to severe LRTIs requiring hospitalizations ([@B3], [@B4]). Innate responses to RSV or pneumococcal bacteria can prime the host for secondary infection by activating inflammatory cells such as macrophages and neutrophils ([@B5], [@B6]). T-helper cell 17 (Th17) responses are important in the control of pneumococcal colonization, which is a pre-requisite step in the development of invasive disease ([@B7]). However, chronic exposure can lead to dysregulated inflammatory responses and pathology. Balancing the inflammatory response during co-infection may be a strategy to reduce severe morbidity ([@B8]).

The discovery of the Vitamin D receptor (VDR) and cytochrome P450 27B1 (CYP27B1) enzyme expression on immune cells has driven exploration into whether the active metabolite of vitamin D, 1,25 dihydroxyvitamin D~3~ \[1,25(OH)~2~D~3~\] (VitD~3~), has immunoprotective properties in the context of infection ([@B9]--[@B12]). Numerous observational data and clinical trials suggest that insufficient VitD~3~ levels are associated with increased susceptibility to respiratory pathogens, and that VitD~3~ supplementation in high disease burden settings may be beneficial ([@B13]--[@B15]). Interactions between the VDR and VitD~3~ mediates anti-inflammatory effects on both the innate and adaptive immune systems, thereby regulating immunity in the context of bacterial and/or viral inflammation. Innate cell subsets including neutrophils, macrophages, and dendritic cells (DCs) all express VDR and respond to VitD~3~. Following contact with pathogens through binding to their toll-like receptors (TLRs), genes that encode up-regulation of the VDR and production of CYP27B1 become expressed ([@B16]). Stimulation of the VDR in these cells enhances their bactericidal, anti-microbial, chemotactic, and phagocytic capabilities ([@B17]). Similarly, VitD~3~ also influences the adaptive immune responses either directly or indirectly through DCs, altering their cytokine production. This influences Th17 activation and function, through increasing IL-10 and decreasing IL-17A secretion, which are associated with RSV and pneumococcal infections ([@B18]).

In this study, we examined the effect of VitD~3~ on inflammatory responses in the context of pneumococcal and RSV co-stimulation. We treated peripheral blood mononuclear cells (PBMCs) isolated from healthy adults with VitD~3~ and stimulated with either pneumococcal whole cell antigen (WCA), RSV or WCA-RSV together to study host cytokine responses and the frequency of key immune cell populations important during pneumococcal and RSV infections, focusing on Th17 (for pneumococcus) and innate (for RSV alone and pneumococcal-RSV co-infection) inflammatory responses. Our results provide evidence that VitD~3~ reduces pneumococcal Th17 responses, but had limited effects in modulating the inflammatory response during pneumococcal-RSV co-stimulation. These findings are important in the context of novel strategies such as VitD~3~ supplementation to reduce the severity and incidence of both pneumococcal and RSV infections in VitD~3~ in high risk populations.

Methods {#s2}
=======

Study Samples
-------------

Twelve healthy adults aged from 19 to 64 years old were enrolled into the study. A single blood sample (\~20 mLs) was collected from each individual into a sodium heparin tube. All subjects gave their informed consent and the study was approved by the Royal Children\'s Hospital Human Research Ethics Committee (HREC).

Materials
---------

The active metabolite of VitD~3~ was purchased from Tocris Bioscience (Bristol, UK). The pneumococcal whole cell antigen (WCA) was kindly provided by PATH under a Materials Transfer Agreement. Live RSV-A2 strain and A549 cell line was purchased from American Type Culture Collection (ATCC; Virginia, USA).

RSV Preparation
---------------

For RSV stock preparation, RSV A2 strain was grown in A549 cells and purified by centrifugation through 30% sucrose layer as described previously ([@B19]). The harvested virus was collected in DMEM culture medium containing 20% sucrose and aliquoted, then snap-frozen and stored at−80°C until subsequent experiments. The titre of purified virus stocks were determined by plaque assay according to a previous method ([@B20]).

PBMC Culture
------------

The PBMCs were isolated immediately after blood collection by density gradient centrifugation using Lymphoprep (Axis-Shield, Oslo, Norway) at 400 × g for 30 min without brake at room temperature (RT). Isolated PBMCs were then washed twice in RPMI-1640 medium (Sigma-Aldrich, St. Louis, USA) supplemented with 10% FBS, 1,000 IU penicillin-streptomycin and 200 nM L-glutamine (RPMI-FBS) at 500 × g for 10 min at RT. The cells were resuspended in 1 mL RPMI-FBS and the cell concentration was determined using the Trypan blue exclusion dye (Sigma-Aldrich, St. Louis, USA) method where a 1:1 mixture of PBMCs and Trypan Blue dye was added to a haemocytometer (Neubauer chamber) and counted under a microscope. For pneumococcal assays, 1 × 10^6^ PBMCs/mL were pre-treated with 100 nmol/L VitD~3~ for 24 h then stimulated with 1 μg/mL WCA for 5 days. Based on a model adapted from previous studies ([@B21]), 1 × 10^6^ PBMCs/mL in our co-stimulation experiments were incubated simultaneously with live RSV (MOI = 1) and 1 μg/mL WCA and 100 nmol/L VitD~3~ for 24 h. Supernatants were then harvested and stored at−30°C until use.

Cytokine Measurement
--------------------

Levels of IFN-γ, IL-8, IL-10, TNF-α, MCP-1, and RANTES in cultured supernatants from PBMCs were measured using a human cytokine multiplex bead array method as per the manufacturer\'s instructions (Milliplex; Millipore Corporation, Billerica, MA, USA). IL-6, IL-17A, and IL-22 were measured using commercial ELISA kits according to the manufacturer\'s instructions (R&D Systems; Minneapolis, Minnesota, USA).

Flow Cytometry
--------------

To identify specific immune cell subsets in PBMCs following VitD~3~ treatment, cells were stained with fluorescently-conjugated monoclonal antibodies; CD4-BUV737, CD45RO-APC, CD161-FITC, CD194-V450, CD196-PE, CD14-BV605, CD19-APC-H7, CD56-BV421, CD282-AF647 (TLR2), CD284-BV786 (TLR4; all from BD Bioscience; San Diego, CA, USA), and anti-TLR7-PE (Gibco Life Technologies, Carlsbad, USA), Zombie Aqua™ Fixable Viability Kit (BioLegend, San Diego, USA). Compensation bead particles were used to account for spectral overlap (BD Bioscience, San Diego, CA, USA) and analyzed using the BD LSRII flow cytometer. Unstained PBMCs and fluorescence minus one (FMO) were used as controls and a minimum of 100,000 events were analyzed per sample gated on live, single cell lymphocyte gate based on FSC and SSC, where the expression of the cell surface molecules was evaluated using FlowJo, LLC v10.4.2 software. Refer to [Supplementary Figures 1--4](#SM1){ref-type="supplementary-material"} for gating strategies.

Statistical Analysis
--------------------

Data is presented as median ± IQR for cytokine and flow cytometry results. Comparison of VitD~3~ treated and untreated cytokine responses and cell populations were determined using a paired non-parametric, Wilcoxon sign-rank test. The data was graphically represented and statistically analyzed using Graphpad prism 6 software (Graphpad Software Inc, California, USA). All tests performed were two-tailed and a *p* \< 0.05 was considered significant.

Results {#s3}
=======

VitD~3~ Reduces Inflammatory Cytokines and Th17 Frequency in PBMCs Following Pneumococcal Stimulation
-----------------------------------------------------------------------------------------------------

We examined the potential for VitD~3~ to modify Th17 responses as this is important in the control of pneumococcal colonization. Pneumococcal WCA was used as this has previously been shown to specifically induce Th17 responses in mice and humans ([@B22], [@B23]). Stimulation of PBMCs with pneumococcal WCA significantly enhanced the proportion of Th17 cells and levels of Th17-related cytokines IL-17A and IL-22 ([Figures 1A--C](#F1){ref-type="fig"}). VitD~3~ significantly reduced the Th17 frequency in both unstimulated and WCA-stimulated PBMCs (both *p* = 0.016; [Figure 1A](#F1){ref-type="fig"}), as well as IL-17A and IL-22 in WCA-stimulated cells compared with untreated cells stimulated with WCA (both *p* \< 0.01; [Figures 1B,C](#F1){ref-type="fig"}). In contrast, VitD~3~ increased IL-10 in WCA-stimulated PBMCs (*p* = 0.001; [Figure 1D](#F1){ref-type="fig"}). Consistent with these findings, the IL-17A/IL-10 and IL-22/IL-10 ratios (both *p* = 0.001) were also significantly decreased by VitD~3~ ([Figures 1E,F](#F1){ref-type="fig"}).

![*VitD*~3~ *decreases pneumococcal Th17 responses*. 1 × 10^6^ PBMCs/mL were pre-treated with 100 nmol/L VitD~3~ for 24 h, prior to stimulation with 1 μg/mL WCA for 5 days. Th17 frequency **(A)** was measured by flow cytometry. Th17 populations were determined by positive staining for cell surface markers obtained from live single lymphocytes. These were considered CD4+CD45+CD161+CD194+CD196+. IL-17A **(B)**, IL-22 **(C)**, IL-10 **(D)**, IL-17A-IL-10 ratio **(E)**, IL-22-IL-10 ratio and **(F)**, concentrations were measured by an ELISA in pg/mL. Open circles represent untreated PBMCs, whilst closed circles represent VitD~3~ treated PBMCs. Data shown represents median ± IQR; *n* = 12 per group for cytokine analyses and *n* = 8 per group for flow cytometry.](fimmu-11-00602-g0001){#F1}

VitD~3~ also significantly reduced the level of IFN-γ, IL-8, and TNF-α in unstimulated cells ([Figures 2A,B,D](#F2){ref-type="fig"}), while in WCA-stimulated cells, VitD~3~ significantly reduced IFN-γ while increasing IL-1β ([Figures 2A,C](#F2){ref-type="fig"}) but did not alter IL-8 or TNF-α levels ([Figures 2B,D](#F2){ref-type="fig"}).

![VitD~3~ reduces pneumococcal pro-inflammatory cytokines and increases anti-inflammatory cytokines. 1 × 10^6^ PBMCs/mL were pre-treated with VitD~3~ (100nmol/L) for 24 h, prior to stimulation with 1 μg/mL WCA for 5 days. **(A)** IFN-γ, **(B)** IL-8, **(C)** IL-1β, and **(D)**. TNF-α concentrations were measured by a multiplex assay in pg/mL. Open circles represent untreated PBMCs, whilst closed circles represent VitD~3~ treated PBMCs. Data shown represents median ± IQR; *n* = 12 per group.](fimmu-11-00602-g0002){#F2}

VitD~3~ Does Not Modulate Inflammatory Responses During Pneumococcal-RSV Co-stimulation
---------------------------------------------------------------------------------------

To determine the effect of VitD~3~ in the context of pneumococcal and RSV co-stimulation, we undertook studies of the innate response using a model adapted from previous studies ([@B21]). Co-stimulation of PBMCs with WCA and RSV (WCA-RSV) resulted in increased cytokine responses for IL-6, IL-10, IL-1β, and TNF-α compared to RSV alone ([Figures 3B--E](#F3){ref-type="fig"}). Compared to WCA stimulation, WCA-RSV significantly increased the level of all cytokines measured ([Figures 3A--G](#F3){ref-type="fig"}). VitD~3~ treatment of WCA-RSV stimulated cells did not affect most cytokines, but increased the levels of IL-1β and RANTES (both *p* \< 0.05; [Figures 3D,G](#F3){ref-type="fig"}).

![The effect of VitD~3~ on pro-inflammatory cytokines, chemokines, and immune cell subsets during bacterial-viral co-stimulation. 1 × 10^6^ PBMCs/mL were treated with VitD~3~ (100 nmol/L) at the time of stimulation. PBMCs were stimulated with live RSV at an MOI = 1, WCA (1 μg/mL) or WCA-RSV (designated "co"). **(A)** IFN-γ, **(B)** IL-6, **(C)** IL-10, **(D)** IL-1β, **(E)** TNF-α, **(F)** MCP-1, and **(G)** RANTES. For immune cell subsets cell populations were determined by positive cell surface staining from live single lymphocytes. **(H)** CD3+, **(I)** CD14+, **(J)** CD19+, **(K)** CD56+. Concentrations were measured by a multiplex assay in pg/mL. Open circles represent untreated PBMCs, whilst closed circles represent VitD~3~ treated PBMCs. Data shown represents median ± IQR; *n* = 8 per group.](fimmu-11-00602-g0003){#F3}

For RSV stimulation alone, VitD~3~ significantly reduced IL-6 only (*p* = 0.023; [Figure 3B](#F3){ref-type="fig"}), but had no effect on any of the other cytokines measured. For WCA alone, VitD3 increased IL-1β only (*p* = 0.016; [Figure 3E](#F3){ref-type="fig"}), consistent with our earlier observation (see [Figure 1](#F1){ref-type="fig"}).

Effect of VitD~3~ on Innate and Adaptive Cell Subsets and TLR Expression Following Pneumococcal-RSV Co-stimulation
------------------------------------------------------------------------------------------------------------------

To understand how VitD~3~ mediates these anti-inflammatory effects, we examined the phenotypic expression of key immune cell markers. We found that VitD~3~ treatment in the absence of any stimulation increased the frequency of CD3+ T cells (*p* = 0.008) while decreasing CD14+ monocyte populations (*p* = 0.039; [Figures 3H--I](#F3){ref-type="fig"}) but had no effect on CD19+ or CD56+ cells ([Figures 3J--K](#F3){ref-type="fig"}). When stimulated with WCA alone, VitD~3~ treatment significantly increased CD3+ cells ([Figure 3H](#F3){ref-type="fig"}) but reduced CD19+ and CD14+ cell numbers compared with untreated PBMCs stimulated with WCA alone ([Figures 3I,J](#F3){ref-type="fig"}), while for RSV alone, VitD~3~ only decreased CD14+ cells ([Figure 3I](#F3){ref-type="fig"}). The CD14+ cell frequency was significantly decreased following WCA or WCA-RSV compared with unstimulated cells (*p* = 0.008 for both; [Figure 3I](#F3){ref-type="fig"}).

VitD~3~ did not modulate the frequency of any of the immune cell populations in the context of WCA-RSV co-stimulation ([Figures 3H--K](#F3){ref-type="fig"}). In the absence of VitD~3~, WCA-RSV co-stimulation significantly increased the percentage of CD3+ cells compared to WCA alone but reduced CD19+ cells compared to RSV alone ([Figures 3H,J](#F3){ref-type="fig"}). Furthermore, CD56+ cells were reduced following stimulation with RSV alone compared with unstimulated cells while WCA-RSV reduced CD56+ cells compared to unstimulated and WCA alone-stimulated cells (*p* = 0.008 for both; [Figure 3K](#F3){ref-type="fig"}).

We next examined TLR expression on PBMCs and specific cell populations to determine whether the effects of VitD~3~ is pathogen or ligand-specific ([Figure 4](#F4){ref-type="fig"}). In unstimulated PBMCs, VitD~3~ significantly reduced the frequency of TLR2+ and TLR4+ cells but only TLR2+ cells following RSV stimulation ([Figures 4A,B](#F4){ref-type="fig"}). TLR7 expression was not modulated by VitD~3~ for any of the conditions tested ([Figure 4C](#F4){ref-type="fig"}). For WCA alone, VitD~3~ did not affect any TLRs. Co-stimulation with WCA-RSV significantly reduced the frequency of TLR2+ cells compared with WCA (*p* = 0.008) or RSV (*p* = 0.016) alone ([Figure 4A](#F4){ref-type="fig"}). However, VitD~3~ only increased the percentage of TLR4+ cells when co-stimulated with WCA-RSV (*p* = 0.039; [Figure 4B](#F4){ref-type="fig"}).

![The effect of VitD~3~ on TLR expression in PBMCs. 1 × 10^6^ PBMCs/mL were treated with VitD~3~ (100 nmol/L) at the time of stimulation. PBMCs were stimulated with live RSV at an MOI = 1, WCA (1 μg/mL) or WCA-RSV (designated "co") prior to phenotyping by flow cytometry. Cell populations were determined by positive staining for cell surface obtained from live single lymphocytes. **(A)** TLR2+, **(B)** TLR4+, **(C)** TLR7+, **(D)** CD14+TLR2+, **(E)** CD14+TLR4+, **(F)** CD14+TLR7+, **(G)** CD56+TLR2+, **(H)** CD56+TLR4+, **(I)** CD56+TLR7+. Open circles represent untreated PBMCs, whilst closed circles represent VitD~3~ treated PBMCs. Data shown represents median ± IQR; *n* = 8 per group.](fimmu-11-00602-g0004){#F4}

Co-stimulation with WCA-RSV significantly reduced the percentage of CD14+TLR2+ compared to RSV or WCA alone ([Figure 4D](#F4){ref-type="fig"}). WCA-RSV had no effect on CD14+TLR4+ cells but significantly increased the frequency of CD14+TLR7+ cells compared with RSV or WCA alone or unstimulated cells ([Figures 4E--F](#F4){ref-type="fig"}). However, VitD~3~ treatment significantly reduced CD14+TLR2+ frequency for RSV (*p* = 0.008) or WCA (*p* = 0.016) stimulation compared with either one alone but not WCA-RSV co-stimulation ([Figure 4D](#F4){ref-type="fig"}). For CD14+TLR4+ cells, VitD~3~ only reduced the frequency in unstimulated cells ([Figure 4E](#F4){ref-type="fig"}), while VitD~3~ significantly increased the percentage of CD14+TLR7+ cells for RSV alone (*p* = 0.039), with non-significant increases for both WCA alone and WCA-RSV conditions ([Figure 4F](#F4){ref-type="fig"}). For CD56+ cells, RSV stimulation increased the percentage of TLR2 (*p* = 0.008) and TLR7 (*p* = 0.016; [Figures 4G,I](#F4){ref-type="fig"}), VitD~3~ however only increased TLR4 frequency for RSV alone stimulation and WCA-RSV co-stimulation (*p* = 0.039) but did not alter TLR2 or TLR7 for any other condition tested ([Figures 4G--I](#F4){ref-type="fig"}).

Discussion {#s4}
==========

Co-infection with *S. pneumoniae* and RSV increases host inflammatory responses that often leads to severe respiratory disease requiring hospitalization. The anti-inflammatory effects of VitD~3~ are well-documented however their ability to modulate responses associated with bacterial or viral exposure are not well understood. This study extends our earlier observations of VitD~3~ effects on pneumococcal innate responses ([@B24]) to examine Th17 immunity and inflammatory responses following co-stimulation with pneumococcus and RSV. We found that VitD~3~ reduced pneumococcal Th17 inflammation but only had a limited effect on responses to WCA-RSV co-stimulation.

Pneumococcal exposure induces Th17 responses that protect against subsequent pneumococcal acquisition by enhancing recruitment of neutrophils and increasing anti-microbial peptide release through IL-17A and IL-22 secretion ([@B25], [@B26]). However, in low-and middle-income countries where pneumococcal carriage is high, a persistent IL-17A response occurs. The high level of exposure to pneumococcus in these settings limits the ability of IL-17A to reduce colonization, persisting to chronic inflammation through continued recruitment of neutrophils and macrophages ([@B27]). We used pneumococcal WCA as this is a well-characterized inducer of Th17 responses, and was a good model to examine the effects of VitD~3~ ([@B7]). We defined Th17 responses on the basis of CCR4 and CCR6 chemokine receptor expression as this has previously been described as a functional Th17 subset ([@B28], [@B29]). This was confirmed by the increased activation of Th17 cells and their related cytokines by WCA. VitD~3~ reduced the Th17 cell frequency and level of IL-17A and IL-22, suggesting a potent anti-Th17 effect. VitD3 also enhanced IL-10, lending support for the Th17-Treg axis ([@B30], [@B31]). This is important since unregulated Th17 responses can lead to significant inflammation and pathology. In view of our findings, VitD~3~ may have a critical role in maintaining the balance between these responses, particularly in populations where there is substantial exposure to pneumococcus during early life.

Increased levels of TNF-α and IL-6 during pneumococcal infection are associated with severity of disease ([@B32]). Pre-treatment with VitD~3~ decreased these cytokines while IL-1β were increased. This is consistent with a recent study by Sommer and Fabri ([@B33]), suggesting that VitD~3~ increases IL-1β to prime the innate response by influencing IL-1β gene transcription as no IL-1β is released prior to infection. This priming of the innate response by VitD~3~ is important to enhance anti-microbial activity through increased defensin-4 secretion ([@B34]--[@B36]). Further, studies to examine the production of antimicrobial peptides such as cathelicidins in response to VitD~3~ would be worthwhile.

To determine the role of VitD~3~ on the response to WCA-RSV co-stimulation, we used a different model to the Th17 studies to determine innate effects, based on a previous study ([@B21]). We observed increased cytokine responses in PBMCs following co-stimulation with WCA and RSV, recapitulating the effect seen during co-infection. Similarly, children given the live attenuated influenza vaccine had increased pneumococcal carriage, possibly due to increased CCR2 inflammatory monocytes which upregulate bacterial adherence receptors ([@B37]). Additionally, pneumococcal carriage also enhances secondary RSV infection. It has been shown that mice carrying pneumococcus prior to RSV infection exhibit much higher viral loads ([@B38]). Thus, the increase in IL-1β and RANTES levels by VitD~3~ is important as this enhances clearance of viral infections such as RSV by recruiting T cells and monocytes to the site of infection ([@B39]).

Monocytes and NK cells are crucial in the clearance of RSV, both contributing to type-1 interferon release to reduce pathology mediated by RSV ([@B40], [@B41]). We found that, VitD~3~ significantly reduced the number of CD14+ monocyte cells in response to WCA or RSV but not for WCA-RSV although a trend toward lower numbers was observed. In contrast, we found VitD~3~ had increased overall TLR4 expression as well as on CD56+TLR4+ cells following co-stimulation. TLR4 on innate cells such as monocytes and NK cells bind LPS which initiates pro-inflammatory responses to pneumococcus and may also interact with the F-protein on RSV, respectively. As macrophage depletion in secondary pneumococcal infection increases pneumococcal dissemination, increased TLR4 expression may be beneficial in reducing its capacity to spread ([@B42]--[@B44]). In CD14+ monocytes, both WCA and RSV stimulation alone had decreased TLR2 expression by VitD~3~, while total TLR2 and TLR4 populations were reduced by VitD~3~ in unstimulated cells. The expression of TLR2 on epithelial cells is upregulated following RSV infection and plays an important role in innate activation. TLR2 deficient mice show impaired neutrophil migration and pro-inflammatory cytokine production by macrophages, alongside uncontrolled RSV replication ([@B45]). Therefore, VitD~3~ appears to restore TLR2 responsiveness by upregulating VDR transcription factors to influence macrophage and neutrophil activity ([@B42]). VitD~3~ also increased CD3 expression on T cells while lowering CD19 expression on B cells for WCA only suggesting that VitD~3~ may also have important regulatory roles in terms of T cell differentiation and antibody production. Prior studies have demonstrated that VitD~3~ can modulate certain T-helper cell populations in the context of pneumococcal stimulation ([@B18]), but the implications on B cell function require further investigation. As we did not measure cell proliferation, we cannot rule out the possibility that the anti-inflammatory effect of VitD~3~ may also involve effects on proliferation.

Interestingly, we found that TLR7 on CD14+ monocytes and TLR4 on CD56+ cells was significantly upregulated by VitD~3~ for RSV and WCA-RSV, while TLR2 was reduced, suggesting that in response to pathogen encounter, VitD~3~ may differentially effect bacterial and viral pattern recognition receptors. RSV has a number of surface proteins that can bind directly with TLR4 and/or TLR7, as well as intracellular receptors such as RIG-I ([@B46]), suggesting that VitD~3~ may be important in regulating viral or viral-bacterial co-infection. Indeed, VitD~3~ has been shown to activate antiviral RIG-I pathways during rotavirus infection of pigs ([@B47]). While TLR7 is mainly expressed intracellularly, it has also been shown to be expressed on the surface of immune cells ([@B48]). Moreover, previous studies have shown that TLR7 responses are impaired in otherwise healthy individuals with low vitamin D levels ([@B49]). Recent evidence has shown that airway neutrophil influx following RSV infection mediates anti-bacterial effects in relation to pneumococcus ([@B50]). We previously found that VitD~3~ was able to reduce neutrophil migration ([@B24]), but how VitD~3~ might regulate this response at the respiratory mucosa during RSV-pneumococcal infection is an important question that remains unanswered.

Respiratory infections are most prevalent during winter when VitD~3~ status is lowest in individuals. Multiple epidemiological studies have suggested VitD~3~ deficiency to be an associated risk factor for susceptibility to respiratory diseases ([@B51], [@B52]). Novel strategies to prevent and/or reduce pneumococcal inflammatory responses are important in the context of secondary viral infections and disease ([@B53]). The effect of VitD~3~ in co-infection models is unknown, and further research into the potential benefits are required ([@B54], [@B55]).

Our study has several limitations, the main one being the small sample size. Despite this, we were still able to demonstrate the anti-inflammatory effects of VitD~3~, similar to other studies ([@B21], [@B56]). While we did not measure VitD~3~ status in our cohort, we have previously shown that most adults in our setting are VitD~3~ insufficient ([@B24]) which may resemble to some extent the VitD~3~ status in other geographical settings. Our results also need to be interpreted with caution as we examined VitD~3~ effects in adults which may not directly translate into a pediatric population ([@B57]). Further, studies in high burden settings or high risk groups \[e.g., preterm infants; ([@B58])\] are required to fully investigate the role of VitD~3~ to protect against severe respiratory infection during early life.

Conclusion {#s5}
==========

Our results suggest that VitD~3~ has important biological effects in the context of bacterial stimulation but was less effective for bacterial-viral co-stimulation, through modulation of innate and adaptive responses important for protection. This effect of VitD~3~ was associated with its effects on Th17 cells as well as expression of TLR responses on key innate cells. Populations most at risk from respiratory infection are generally VitD~3~ deficient, and this is associated with increased cytokine responses that promote disease severity. Future studies should aim to examine the effect of VitD~3~ during co-infection, using PBMCs from pediatric cohorts to better determine the potential efficacy of VitD~3~ trials in high-risk populations.
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